A growing number of athletes are skipping the operating room entirely, opting instead for injectable treatments that promise to repair damaged tendons without the months-long recovery that surgery demands. In a study of 51 former NFL players who received stem cell injections for joint injuries, 70 percent reported significant improvement in both pain and functionality one year later, and 47 of the 51 players — 92 percent — avoided surgery altogether. Names like Tiger Woods, Rafael Nadal, and Peyton Manning have all credited injectable therapies with helping them return to competition faster than traditional surgical timelines would allow.
But the picture is not as straightforward as those headline cases suggest. Higher-quality randomized controlled trials have shown no clear benefit of platelet-rich plasma over placebo for certain tendon conditions, and many of the most promising injectable treatments remain under investigation or lack FDA approval. The science is advancing rapidly — the global orthobiologics market is valued at roughly $6.68 billion in 2025 and projected to reach $9.52 billion by 2031 — but patients considering these options need to understand both what works and what remains unproven. This article examines the injectable treatments currently available for tendon injuries, reviews the clinical evidence for and against them, profiles athletes who chose injections over surgery, and explores what recent FDA activity and ongoing trials mean for the future of non-surgical tendon repair.
Table of Contents
- What Injectable Treatments Are Replacing Surgery for Tendon Injuries in Athletes?
- What Does the Clinical Evidence Actually Show About Injectable Tendon Treatments?
- Which Professional Athletes Have Chosen Injectables Over Surgery?
- How Do the Costs and Tradeoffs of Injectables Compare to Surgery?
- What Are the Risks and Limitations Patients Should Know About?
- What New FDA-Cleared Products Are Entering the Market?
- Where Is Non-Surgical Tendon Treatment Headed?
- Conclusion
- Frequently Asked Questions
What Injectable Treatments Are Replacing Surgery for Tendon Injuries in Athletes?
The most established injectable option is platelet-rich plasma, or prp, which concentrates a patient’s own platelets and growth factors and delivers them directly into damaged tissue. PRP has regulatory approval for clinical use in treating conditions like tennis elbow, Achilles tendinitis, and rotator cuff injuries. A single PRP injection costs approximately $707 in the United States, making it considerably more accessible than surgery — both financially and in terms of downtime. Mesenchymal stem cell injections represent a more aggressive approach, helping reorganize collagen and reduce fibrosis in injured tendons. These run about $2,728 per injection, though MSC therapy has not achieved widespread clinical approval due to inconsistent results across different cell preparation methods.
Beyond PRP and stem cells, prolotherapy — which involves injecting dextrose solutions into damaged ligament and tendon structures — has built a solid research base, particularly for knee arthritis and tennis elbow. Then there is BPC-157, a peptide therapy that has shown real promise in preclinical studies for promoting healing in tendon ruptures, ligament tears, and muscle injuries. However, BPC-157 lacks FDA approval and is banned in professional sports, which limits its legitimate use despite the buzz surrounding it in athletic circles. The key distinction between these treatments and surgery is recovery time. A tendon repair surgery typically requires weeks of immobilization followed by months of rehabilitation. Injectable treatments, by contrast, often allow athletes to begin movement within days. That difference alone explains why so many professional athletes have gravitated toward these options, even when the evidence base remains incomplete.
What Does the Clinical Evidence Actually Show About Injectable Tendon Treatments?
The clinical data on injectables tells two very different stories depending on the condition being treated and the rigor of the study design. That 92 percent surgery-avoidance rate among former NFL players is compelling, but it involved athletes with arthritis in shoulders, hips, and knees — not necessarily acute tendon tears. When researchers have looked specifically at tendon injuries using higher-quality study designs, the results have been far less encouraging. A randomized clinical trial published in JAMA examined PRP for chronic Achilles tendinopathy and found that PRP injection did not result in improved functional scores over three months compared to placebo, though it did increase tendon thickness. A separate study on acute Achilles tendon rupture found that PRP improved long-term ankle mobility but had no significant effect on functional scores or return to sport when compared to placebo.
A broader meta-analysis of PRP for Achilles tendinopathy in athletes specifically found no clear benefit over placebo. These are not minor caveats — they suggest that the most widely available injectable treatment may not outperform doing nothing for certain tendon conditions. However, if your injury involves a partial tear rather than complete rupture, or if you are dealing with chronic tendinopathy rather than acute damage, the calculus may be different. PRP and stem cell injections appear to perform better in conditions where the goal is to stimulate a healing response in tissue that has stalled in its recovery, rather than to repair a fully severed tendon. Patients should be wary of clinics that present injectables as universally superior to surgery without specifying which conditions and injury grades they are most appropriate for.
Which Professional Athletes Have Chosen Injectables Over Surgery?
The list of high-profile athletes who have turned to injectable treatments reads like a hall of fame roster. LaRon Landry, the NFL safety, used PRP treatments for a torn Achilles tendon instead of undergoing surgery — a decision that raised eyebrows at the time but helped normalize the approach for other professional athletes. Ahmad Bradshaw of the New York Giants chose stem cell injections to promote bone regrowth in his foot rather than submit to yet another surgery on a body that had already been through multiple operations. Peyton Manning traveled to Germany for stem cell treatment on a neck injury, a decision that attracted both admiration and criticism given the experimental nature of the procedure at the time. Max Scherzer, the dominant pitcher, and Tiger Woods both credited regenerative injection therapies with helping them extend careers that seemed to be winding down due to cumulative physical damage.
These cases are powerful anecdotes, but they come with an important asterisk: professional athletes have access to the best practitioners, the most carefully prepared biologics, and comprehensive rehabilitation programs that most patients will never see. The results a world-class athlete achieves with a stem cell injection administered by a top sports medicine specialist and supported by a team of physical therapists may not translate to the average weekend runner visiting a strip-mall regenerative medicine clinic. That said, these athlete cases have done something valuable by forcing the conversation about non-surgical options into the mainstream. Twenty years ago, a torn tendon meant surgery, full stop. The fact that elite athletes — people whose livelihoods depend on peak physical performance — are willing to bet their careers on injectables speaks to a genuine shift in how the sports medicine community views these treatments.
How Do the Costs and Tradeoffs of Injectables Compare to Surgery?
The financial comparison between injectables and surgery favors injections on the surface. A single PRP injection at approximately $707 is a fraction of what tendon surgery costs when you factor in surgical fees, anesthesia, facility charges, and post-operative rehabilitation. Even mesenchymal stem cell injections at roughly $2,728 per treatment are often less expensive than surgical intervention. But costs can compound quickly — many injectable protocols call for multiple sessions spaced weeks apart, and insurance coverage for regenerative treatments remains spotty at best. Most PRP and stem cell treatments are paid entirely out of pocket. Surgery, for all its drawbacks, offers something injectables currently cannot guarantee: structural repair.
When a tendon is fully ruptured, no injection can physically reconnect the severed ends. Injectables work by stimulating the body’s own healing mechanisms — concentrating growth factors, recruiting stem cells, reducing inflammation — but they depend on there being enough intact tissue to work with. For partial tears and chronic tendinopathy, this biological approach can be effective. For complete ruptures, surgery remains the standard of care. There is also the question of older injectable approaches that injectables are replacing. Corticosteroid injections have been a mainstay of orthopedic pain management for decades, but they come with serious risks: some studies have documented tendon rupture complication rates as high as 39 percent with repeated corticosteroid use. The newer biological injectables — PRP, stem cells, prolotherapy — avoid this tissue-degradation problem because they work with the body’s healing processes rather than simply masking inflammation.
What Are the Risks and Limitations Patients Should Know About?
The biggest limitation of injectable tendon treatments is the gap between marketing claims and clinical evidence. Many regenerative medicine clinics advertise these therapies as proven alternatives to surgery, but most injectable orthobiologic products beyond autologous treatments like PRP remain under investigation or are awaiting FDA approval. The difference between a treatment that is available and a treatment that is proven effective is enormous, and patients should not confuse the two. BPC-157 illustrates this problem well. Preclinical studies — meaning laboratory and animal research — show genuine promise for tendon healing, but the peptide has no FDA approval and is banned in professional sports.
Patients who seek it out are essentially self-experimenting with a substance that has not been validated in rigorous human trials. Similarly, mesenchymal stem cell therapy has shown mixed results across different studies, largely because there is no standardized protocol for how the cells should be prepared, concentrated, or delivered. Two clinics offering “stem cell injections” may be providing very different products. Patients should also understand that injectable treatments are not risk-free. While they avoid the infection risks and anesthesia complications associated with surgery, injection-site reactions, temporary pain flares, and treatment failure are all real possibilities. The most important step any patient can take is to ask their provider pointed questions: What specific injectable are you recommending? What is the evidence base for this treatment in my specific condition? What is your success rate, and how do you define success? Providers who cannot or will not answer these questions clearly deserve skepticism.
What New FDA-Cleared Products Are Entering the Market?
Recent FDA activity suggests the regulatory landscape for orthobiologic injectables is shifting. In 2025, Alafair Biosciences received FDA 510(k) clearance for its VersaCoat tendon protector, and TBYR Health gained clearance for its B3 gel system — a bioresorbable gel barrier designed to support recovery after tendon, ligament, and skeletal muscle surgery. These are not injectable treatments in the traditional sense, but they represent the broader push toward biological solutions for musculoskeletal injuries.
On the clinical trial front, Ingeneron is running a pivotal 246-patient study examining an adipose-derived stromal vascular fraction device for rotator cuff tears, though the timeline has been pushed to 2026. If this trial produces positive results, it could pave the way for FDA-approved, standardized stem cell treatments for specific tendon injuries — addressing the inconsistency problem that has plagued mesenchymal stem cell therapy. The orthobiologics market’s projected growth to $9.52 billion by 2031 reflects industry confidence that these regulatory and clinical milestones will be reached, driven in part by rising rates of sports-related injuries and growing patient demand for minimally invasive options.
Where Is Non-Surgical Tendon Treatment Headed?
The trajectory of injectable tendon treatments points toward greater specificity and standardization. The current era — where a patient might receive a PRP injection prepared differently at every clinic — is likely a transitional phase. As clinical trials like the Ingeneron rotator cuff study report results, and as FDA clearances accumulate, the field will move toward standardized protocols with predictable outcomes.
The question is not whether injectables will replace surgery for tendon injuries, but which injuries, in which patients, under which conditions. For patients weighing their options today, the most honest assessment is this: injectable treatments represent a legitimate and growing alternative to surgery for certain tendon injuries, particularly partial tears and chronic tendinopathy that has not responded to physical therapy. They are not a universal replacement for surgical repair, and anyone who tells you otherwise is selling something. The athletes who have benefited most from these treatments had the advantage of expert medical guidance and realistic expectations — two things every patient should demand before consenting to any procedure.
Conclusion
Injectable treatments for tendon injuries have moved well past the experimental phase for some conditions, with PRP now a clinically approved option and stem cell therapies showing meaningful results in studies of professional athletes. The 92 percent surgery-avoidance rate among former NFL players and the endorsements of athletes like Tiger Woods and Peyton Manning reflect a real shift in sports medicine. But the evidence is decidedly mixed for specific conditions — particularly Achilles tendinopathy, where rigorous trials have shown no clear advantage of PRP over placebo.
The practical takeaway is that injectables deserve serious consideration as part of the treatment conversation for tendon injuries, but they should not be treated as a guaranteed alternative to surgery. Patients should seek providers who are transparent about the evidence, specific about the type of injectable being used, and honest about expected outcomes. As the orthobiologics field matures through ongoing FDA activity and larger clinical trials, the line between proven and experimental will become clearer — but for now, informed skepticism remains the healthiest approach.
Frequently Asked Questions
Does insurance cover PRP or stem cell injections for tendon injuries?
Most PRP and stem cell treatments are not covered by insurance and must be paid out of pocket. A single PRP injection costs approximately $707, while a mesenchymal stem cell injection averages around $2,728 in the United States. Some clinics offer payment plans, but patients should budget for multiple sessions if their protocol requires them.
Can injectables fix a completely torn tendon?
No. Injectable treatments work by stimulating the body’s own healing processes in tissue that is still partially intact. For complete tendon ruptures, surgery remains the standard of care because the severed ends must be physically reconnected. Injectables are most appropriate for partial tears and chronic tendinopathy.
Is BPC-157 a safe option for tendon healing?
BPC-157 has shown promise in preclinical studies for promoting healing in tendon ruptures and ligament tears, but it lacks FDA approval and is banned in professional sports. No rigorous human clinical trials have validated its safety or efficacy, so using it amounts to self-experimentation with an unregulated substance.
How long does it take to see results from a PRP injection for a tendon injury?
Most protocols suggest evaluating results over a three- to six-month window. The JAMA trial on chronic Achilles tendinopathy measured outcomes at three months and found no functional improvement over placebo, though tendon thickness did increase. Patients should be cautious about providers who promise rapid results.
Are corticosteroid injections still a good option for tendon pain?
Corticosteroid injections can provide short-term pain relief but carry significant risks with repeated use, including tendon rupture — with complication rates as high as 39 percent in some studies. Newer biological injectables like PRP and prolotherapy are increasingly preferred because they support healing rather than simply suppressing inflammation.
